Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ligand Pharmaceuticals Inc (NASDAQ:LGND)

Delayed Data
As of Dec 09
 +0.85 / +0.82%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Its products address the unmet medical needs of patients for a broad spectrum of diseases, including hepatitis, muscle wasting, alzheimer's disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis. The company operates its business through two segments: CyDex and Ligand. The CyDex segment engages in development and commercialization of drugs using Captisol technology by CyDex Pharmaceuticals, Inc. Ligand Pharmaceuticals was founded by Ronald M. Evans in 1987 and is headquartered in La Jolla, CA.

Contact Information

Ligand Pharmaceuticals, Inc.
11119 North Torrey Pines Road
La Jolla California 92037
P:(858) 550-7500
Investor Relations:



Mutual fund holders65.89%
Other institutional54.59%
Individual stakeholders19.58%

Top Executives

John L. HigginsChief Executive Officer & Director
Matthew W. FoehrPresident & Chief Operating Officer
Vincent AntleVP-Technical Operations & Quality Assurance
Charles S. BerkmanSecretary, Vice President & General Counsel
James D. PipkinVice President-New Product Development